Alpharma Inactive 10-Q2002 Q3 Quarterly report

Filed: 14 Nov 02, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accelerated, acceleration, accreted, achieve, ad, addressing, adhere, Administrative, aid, alert, audit, auditor, bas, began, beneficial, beneficially, biopharmaceutical, Biotech, budgeted, CEO, CFO, Chief, clusivity, Columbia, comment, Committee, commodity, communicated, communication, complement, conduct, consecutive, constant, constitute, construction, contract, Copenhagen, cure, decided, default, documented, enforce, ensure, equal, establish, established, exceeded, Executive, expended, facing, February, fluctuation, food, France, French, furt, Germany, growing, halted, Haute, hold, inability, Indiana, Instance, intense, introducing, introduction, key, knowledge, Kroner, lack, Lasalocid, lead, leaner, lease, leasing, level, license, light, long, lot, manual, meet, methodology, monthly, Norwegian, observation, ordinated, organic, oversee, parking, participation, penetration, pension, permanently, pork, prepay, prevail, procedure, produc, producing, prohibit, project, Pty, reborrowed, receipt, reevaluate, reevaluated, renegotiation, rental, Reporcin, resistance, resolved, respond, return, royalty, satisfactory, Sept, service, SGA, similar, site, Skoyen, slower, soft, Southern, structure, study, suggest, summarize, Terre, ts, typically, unclear, undertook, upgrading, upheld, versely, viability, Vice, worldwide, yield

Removed: condition, continuing, evidence, fully, governmental, importation, limit, negative, prevent, resultant, reverse, substantially, unsuccessful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Alpharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Alpharma Inc. (the "Company") on Form 10-Q for the period ending September 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ingrid Wiik, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: November 14 , 2002

/s/ Ingrid Wiik

Ingrid Wiik
President and Chief Executive Officer

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: November 14, 2002

/s/ Matthew Farrell

Matthew Farrell
Executive Vice President and
Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.